Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Sagimet Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
SGMT
Nasdaq
8731
https://sagimet.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Sagimet Biosciences Inc
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
- May 6th, 2024 12:00 pm
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
- Apr 22nd, 2024 12:00 pm
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
- Mar 27th, 2024 8:01 pm
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
- Mar 25th, 2024 11:00 am
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
- Mar 25th, 2024 10:15 am
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
- Feb 29th, 2024 1:00 pm
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
- Jan 26th, 2024 1:58 am
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
- Jan 23rd, 2024 10:45 pm
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
- Jan 22nd, 2024 12:00 pm
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic
- Dec 4th, 2023 1:00 pm
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
- Nov 28th, 2023 1:00 pm
Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
- Nov 22nd, 2023 1:00 pm
Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
- Nov 13th, 2023 1:00 pm
Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023
- Nov 10th, 2023 1:30 pm
Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023
- Oct 24th, 2023 3:00 pm
Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
- Oct 18th, 2023 8:05 pm
Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
- Sep 27th, 2023 8:05 pm
‘Load Up,’ Says Goldman Sachs About These 2 ‘Strong Buy’ Stocks
- Aug 29th, 2023 2:21 pm
Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
- Aug 21st, 2023 8:02 pm
Sagimet Biosciences Announces Closing of Underwriters’ Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering
- Aug 15th, 2023 8:04 pm
Scroll